FDA Approves Expanded Use of Sapien 3 for Valve-in-Valve Treatment
Today FDA approved Edwards Lifesciences, LLC’s Sapien 3 Transcatheter Heart Valve for use as a valve-in-valve treatment in instances when bioprosthetic mitral or aortic valves fail. The expanded indication is for use in patients who are at high or greater risk of complications from repeat surgery, said Bram Zuckerman, M.D., director of the division of cardiovascular devices at CDRH in a press release. “This new approval offers U.S. patients with failing surgical bioprosthetic aortic or mitral valves a less-invasive treatment option,” Zuckerman stated.
Valve-in-valve procedures involve the insertion of the replacement valve into a failing surgical bioprosthetic valve via a blood vessel or a small incision in the chest. The procedure serves as an alternative to repeat surgery.
In making the decision, FDA looked at data from 314 patients who had mitral valve-in-valve surgery who are part of the Transcatheter Valve Therapy Registry, which collects clinical data on the safety and effectiveness of Transcatheter valve replacement procedures that are performed in a real-world setting. The data revealed that more than 85% of patients who underwent aortic or mitral valve-in-valve procedures had a clinically meaningful improvement in their heart value systems 30 days after the procedures.
Edwards must participate as a stakeholder of the Transcatheter Valve Therapy Registry to ensure FDA surveillance of the Sapien 3 valve for the next five years.
Related Articles
-
As wearables for smart monitoring require efficient components, it is estimated that 67 percent more 3D printers will be sold this year, than in the previous year, and the medical field is an area of application with great potential.
-
FDA has granted a first-of-its-kind expanded approval for Medtronic's CoreValve System for valve-in-valve replacement.
-
The market value for transcatheter heart valves will exceed $3 billion by 2020, and adoption of next-generation valves will drive significant market growth, provided that positive clinical data continues, according to research and consulting firm GlobalData.
-
The HALO trial represents a new opportunity for surgeons seeking a valve replacement for pediatric patients with no alternative approved treatment options.
